A convenient method to generate and maintain poly(A)-encoding DNA sequences required for *in vitro* transcription of mRNA

Patrick Arbuthnot^{*1}, Abdullah Ely¹ & Kristie Bloom¹

ABSTRACT

Generating mRNA *in vitro* to encode therapeutic or cell-modifying proteins is rapidly gaining favor. An important factor that determines efficiency of translation from *in vitro* transcribed mRNA is the length of the 3' poly(A) sequence. However, reproducibly generating and maintaining templates from circular plasmids to have consistent lengths of the homo poly(A) sequences is challenging. The procedure reported here entails repeated restriction digestion with type IIS enzymes, ligation and circular plasmid propagation. The homopolymeric sequence of approximately 100 bp that is generated using the method is approximately equal to the number of 3' A residues found in the mRNA of mammalian cells. Evaluating expression *in vivo* of a reporter transcript produced using this method showed efficient expression *in vivo*.

METHODS SUMMARY

A method that uses type IIS restriction enzymes to build a poly(A:T) tract of an mRNA-encoding sequence within a circular plasmid is described. Repeated asymmetric cleavage followed by ligation enables lengthening of the homo tract to an approximate maximum of 100 poly(A:T) base pairs. mRNA transcribed from this template is efficiently translated *in vivo*.

KEYWORDS:

in vitro transcription • mRNA • plasmid • poly(A) • type IIS restriction enzymes

¹Wits/SAMRC Antiviral Gene Therapy Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Private Bag 3, WITS 2050, Johannesburg, South Africa; ^{*}Author for correspondence: Patrick.Arbuthnot@wits.ac.za

BioTechniques 66: 37-39 (January 2019)
10.2144/btn-2018-0120

Use of mRNA to encode therapeutic, cell-modifying or immunogenic proteins has recently gained popularity [1]. Valuable features of mRNA for such application are: 1) a cytoplasmic site of action, unlike DNA, which simplifies delivery when formulated in synthetic nonviral vectors; 2) RNA is shortlived *in vivo* to make control of dose easier to achieve; and 3) mRNA does not recombine with DNA, and resultant mutation of the host genome is avoided.

For large-scale preparation of mRNAs *in vitro*, sequences are typically generated using T7 RNA polymerase. Products of the transcription reaction usually have a 5' CAP or internal ribosomal entry site (IRES), 5' untranslated region (5'UTR), protein-coding open reading frame (ORF), 3'UTR and poly(A) sequences at the 3' end. The number of A residues at the 3' end of mRNA is variable and has been reported to range between 67 to 96 nt in actively translated mRNAs of mammalian cells [2]. Ensuring an optimal length of the poly(A) tail is vital for efficient translation and shortening of these sequences leads to decay of mRNA (reviewed in [3,4]). Multiple A residues may be added to synthetic RNA using a poly(A) polymerase from *Escherichia coli* (EPAP) [5] or during transcription from an encoding template [6,7]. When using EPAP to add A residues to the 3' end of mRNA, achieving consistency of the tail lengths may be difficult [6,7]. A complication of using poly(A:T)-containing circular plasmids is that the homopolymeric A:T base pairs in these vectors are unstable and prone to shortening during replication in bacteria [6,8]. Use of a linear plasmid vector was recently employed to increase stability of longer poly(A:T) tracts [6].

To improve on generating poly(A)-encoding templates from widely used circular plasmid DNA, we developed template DNA that may be lengthened using standard procedures of restriction

digestion with ligation and propagation in bacteria. The starting DNA used to engineer the plasmid DNA sequences is depicted in Figure 1A. An mRNA-generating plasmid with 5'UTR comprising the entire IRES of hepatitis C virus (HCV) [9] and 3'UTR derived from human β -globin was generated in house. Insertion of a gene of interest, which was *Firefly Luciferase (FLuc)* in the example used here, was achieved using Gibson assembly [10]. The sequence of the poly(A:T)-encoding region comprised 13 A:T base pairs with flanking *FaqI* and *BclI* type IIS restriction sites. The *BclI* site was positioned at the 5' end and the *FaqI* site at the 3' end of the poly(A:T)-encoding sequence. These type IIS restriction enzymes have unique cleavage sites in the poly(A:T) flanking regions. Orientation of the recognition sites was such that the enzymes each cleaved asymmetrically within the poly(A:T) sequence to generate complementary sticky ends comprising four T or A overhangs. In addition, a *SapI* restriction site was placed immediately 3' of the poly(A:T) tracts, and this enzyme was used to linearize the plasmid to generate a template for *in vitro* transcription. A *SapI* site that naturally occurs within the *FLuc* ORF was abolished using site-directed mutagenesis while retaining the amino acid sequence of the reporter enzyme. The first step of the process to lengthen the A:T sequence entailed two independent double digestions of the plasmid (Figure 1B). After cleavage with *BclI* and *Scal* or *FaqI* and *Scal* according to procedures recommended by the supplier of the enzymes (New England Biolabs, MA, USA), fragments that each contained the longer poly(A:T) sequences were purified. A replicative plasmid was reconstituted after ligation (T4 DNA ligase, ThermoFisher, MA, USA) and propagated in chemically competent bacteria of the XL1-Blue strain (Agilent Technologies, CA, USA). *Scal* has a unique recognition site ►

Figure 1. Principle underlying the method for elongating and maintaining poly(A)-encoding sequences embedded within a plasmid. (A) Complementary oligonucleotides with a short (13 nt) length of poly(A:T) are inserted immediately downstream of a 3' untranslated region (3' UTR) of an mRNA-encoding cassette. In addition to the poly(A:T) sequence, type IIS restriction enzyme recognition sites (*Bve* I, *Sap* I and *Faq* I) are positioned so that cleavage by each would occur within the poly(A:T) region of a typical mRNA transcription template. (B) Digestion with *Faq* I or *Bve* I generates complementary 4 nt overhangs comprising T or A homotetramers. Repeated codigestion with *Scal*, selection of the appropriate restriction fragments then ligation enables lengthening of Poly(A:T) sequences. *Nhe* I and *Bam* HI restriction sites flank the poly(A:T) sequence. (C) Sanger sequencing of plasmids generated after six cycles showed that the poly(A:T) tract was approximately 96 nt in length, and sequence reads beyond the homopolymer were unreliable. (D) Restriction digestion with *Nhe* I and *Bam* HI, which have recognition sites flanking the poly(A:T) sequence, allows approximation of the length of the area of interest. A maximum lengthening of the homopolymeric sequence is achieved after six cycles of digestion, ligation and plasmid propagation. Thereafter variation in the poly(A:T) tract was observed. (E) RNA generated from linearized templates lacking FLuc showed lengthening of the transcripts that correlated with increased span of the poly(A) tract. (F) Bioluminescence imaging and analysis following hydrodynamic injection of 5 μ g of mRNA encoding FLuc. After an exposure of 60 seconds 1.045 $\times 10^7$ photons were detected in the region of interest.

therefore estimated from the length of restriction fragments that encompassed the region of interest (Figure 1D). Our observations indicated a maximum length of the poly(A:T) tract of 80 to 100 bp was achieved after six cycles of the repeated cloning process. This is similar to naturally occurring poly(A) in mRNA and should be suitable for intracellular translation [2]. Information available online indicates that this length of the poly(A)-encoding sequences also exceeds what can typically be guaranteed by commercial suppliers of synthetic duplex DNA. Linear templates derived from intermediates of the sequential steps of the cloning reactions, which lacked FLuc sequences, were used to generate mRNA using T7 RNA polymerase (TranscriptAid T7 High Yield Transcription Kit, ThermoFisher). Electrophoretic resolution of the mRNA confirmed increasing lengths of the transcripts, which correlated with the lengthening poly(A)-containing 3' ends of the mRNA (Figure 1E).

To evaluate whether the poly(A)-containing mRNA sequences were functional, FLuc-encoding plasmid DNA was also linearized with *Sap* I and transcribed *in vitro* using T7 RNA polymerase. Assessment of translation from the template *in vivo* was determined using an institutionally approved protocol (AESC 2018/21/5C) for transfection of murine hepatocytes using hydrodynamic injection [11]. Expression of FLuc in the liver was measured using standard bioluminescence imaging with an IVIS Kinetic Bioluminescence imager (PerkinElmer, MA, USA). Representative data obtained 3 h after administration of 5 μ g of mRNA are shown in Figure 1F. After an exposure of 60 s, 1.045 $\times 10^7$ photons were detected in the region of interest over the liver of the mouse shown in Figure 1F. This value is comparable to that observed after similar administration of commercially available FLuc-encoding mRNA (Trilink, CA, USA). These data verify that the poly(A) tail of the *in vitro* transcribed transcript was functional *in vivo*.

The simple method described here is convenient for propagation of plasmids with transcripts that may be used to serve as templates for preparation of efficiently translated mRNA. Moreover, should shortening of the sequence occur, reconstitution

► within the ampicillin resistance gene and was selected to minimize generation of unintended plasmid clones. The plasmid formed following this initial digestion and ligation should thus have contained a poly(A:T) sequence of 18 bp. Restriction digestion and ligation of the plasmids were repeated and the poly(A:T) tract lengthened

with each successive cycle. Theoretically the length of the poly(A:T) sequence would be increased to 28, 48, 88 and then 168 bp for the second to fifth cloning cycles, respectively. Precise measurement of the number of A:T base pairs was not possible using standard Sanger sequencing (Figure 1C) and the length of the homo tract was

of the length of the poly(A) tract could be conveniently achieved.

AUTHOR CONTRIBUTIONS

PA conceived the idea, carried out most of the DNA manipulation and *in vitro* transcription with contributions from KB. AE performed the hydrodynamic injection and bioluminescence analysis. The manuscript was initially drafted by PA and finalized with input from AE and KB.

FINANCIAL & COMPETING INTERESTS DISCLOSURE

Financial assistance of the authors' laboratory, which was received from the South African Medical Research Council, National Research Foundation, Johnson & Johnson Innovation and the Poliomyelitis Research Foundation, is gratefully acknowledged. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in

the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

OPEN ACCESS

This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>

REFERENCES

1. Sahin U, Kariko K, Tureci O. mRNA-based therapeutics – developing a new class of drugs. *Nat. Rev. Drug Discov.* 13(10), 759–780 (2014).
2. Subtelny AO, Eichhorn SW, Chen GR, Sive H, Bartel DP. Poly(A)-tail profiling reveals an embryonic switch in translational control. *Nature* 508(7494), 66–71 (2014).
3. Chen CY, Shyu AB. Mechanisms of deadenylation-dependent decay. *Wiley Interdiscip. Rev. RNA* 2(2), 167–183 (2011).
4. Jalkanen AL, Coleman SJ, Wilusz J. Determinants and implications of mRNA poly(A) tail size – does this protein make my tail look big? *Semin. Cell Dev. Biol.* 34, 24–32 (2014).
5. Cao GJ, Sarkar N. Identification of the gene for an *Escherichia coli* poly(A) polymerase. *Proc. Natl Acad. Sci. USA* 89(21), 10380–10384 (1992).
6. Grier AE, Burleigh S, Sahni J *et al.* pEVL: a linear plasmid for generating mRNA IVT templates with extended

encoded Poly(A) sequences. *Mol. Ther. Nucleic Acids* 5, e306 (2016).

7. Holtkamp S, Kreiter S, Selmi A *et al.* Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. *Blood* 108(13), 4009–4017 (2006).
8. Tautz D, Schlotterer C. Simple sequences. *Curr. Opin. Genet. Dev.* 4(6), 832–837 (1994).
9. Takamizawa A, Mori C, Fuke I *et al.* Structure and organization of the hepatitis C virus genome isolated from human carriers. *J. Virol.* 65(3), 1105–1113 (1991).
10. Gibson DG, Young L, Chuang RY, Venter JC, Hutchison CA 3rd, Smith HO. Enzymatic assembly of DNA molecules up to several hundred kilobases. *Nat. Methods* 6(5), 343–345 (2009).
11. Yang PL, Althage A, Chung J, Chisari FV. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. *Proc. Natl Acad. Sci. USA* 99(21), 13825–13830 (2002).

OLYMPUS

Your Vision, Our Future

Discover the Possibilities

with the FLUOVIEW® FV3000 Confocal Laser Scanning Microscope

Advance your research with the next evolution of confocal laser scanning microscope technology

Captured using a 1.25x objective on the FV3000 system

- Capture up to 438 frames per second
- Optimized for live cell imaging with high-efficiency TruSpectral detection on every channel
- Designed for easy “macro to micro” imaging from 1.25x to 150x
- Fully upgradable modular design with up to 4 channels of high-sensitivity GaAsP detection

Your Science Matters™

Contact your local Olympus confocal sales representative or visit: www.olympus-lifescience.com to learn more.